Valderm ApS
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Valderm ApS - overview
Established
2003
Location
-, -, Denmark
Primary Industry
Pharmaceuticals
About
Valderm ApS is focused on the development of the second generation anthracycline valrubicin for innovative once daily topical treatment of hyperproliferative skin diseases e. g. psoriasis.
Current Investors
SEED Capital
Primary Industry
Pharmaceuticals
Sub Industries
Pharmaceutical Research & Development, Biomaterials
Website
www.valderm.dk
Company Stage
Series A
Total Amount Raised
Subscriber access only
Valderm ApS - financials
| Fiscal Year Ended | Dec 31, 2005 | Dec 31, 2006 | Dec 31, 2007 | Dec 31, 2008 | Dec 31, 2009 | Dec 31, 2010 | Dec 31, 2011 | Dec 31, 2012 | Dec 31, 2013 | Sep 18, 2014 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (USD) | - | - | - | - | - | - | - | - | - | - |
| % Revenue Growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| EBITDA (USD) | (520,248) | (1,734,494) | (8,918,060) | (11,258,688) | (8,519,872) | (7,279,805) | (4,713,193) | - | - | - |
| Operating Income (USD) | (520,248) | (1,734,494) | (8,918,060) | (11,258,688) | (8,519,872) | (7,279,805) | (4,713,193) | - | - | - |
| Operating Margin | - | - | - | - | - | - | - | - | - | - |
| % EBITDA Margin | - | - | - | - | - | - | - | - | - | - |
| NET Income (USD) | (519,774) | (1,918,961) | (8,840,933) | (10,830,702) | (8,418,562) | (7,310,432) | (4,691,239) | - | - | - |
| % Net Margin | - | - | - | - | - | - | - | - | - | - |
Valderm ApS - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.